Table 2.

Changes in pulmonary physiology before and after therapy with MMF:

Cohort	FVC (L) Δ pre-MMF, Δ post-MMF Diff (SD), p value		DLCO (L) Δ pre-MMF, Δ post-MMF Diff (SD), p value
Entire cohort	6 months -0.047,-0.118 0.071 (0.53), 0.47 n=29	12 months -0.057,-0.015 0.042 (0.45), 0.62 n=29	6 months 0.30,-0.02 -0.32(3.15), 0.72 n= 13	12 months -1.65,0.08 1.74 (3.33), 0.07 n=14
Pulmonary Indication for IS Therapy	6 months -0.07,-0.10 -0.02 (0.52), 0.86 n=19	12 months -0.10,-0.04 0.07 (0.51), 0.59 n=18	6 months 0.39,0.15 -0.24 (2.97), 0.79 n=11	12 months -1.60,-0.21 1.39 (3.23), 0.21 n=10
Treatment Failure	6 months 0.01,-0.18 -0.19 (0.52), 0.28 n=17	12 months -0.02,-0.04 -0.02 (0.34), 0.84 n=18	6 months 0.02,0.63 0.61 (3.28), 0.61 n=8	12 months -1.51,0.41 1.1 (3.34), 0.35 n=9
Intolerance to Current Therapy	6 months -0.15,-0.02 0.12 (0.49), 0.43 n=11	12 months -0.12,0.02 0.14 (0.6), 0.47 n=11	6 months 0.75,-1.06 -1.82 (2.54), 0.18 n=5	12 months -1.92,0.96 2.87 (3.35), 0.13 n=5

Abbreviations: MMF: Mycophonelate Mofetil, Δ pre-MMF: change in value from time point before starting MMF to start of MMF, Δ post-MMF: change in value from starting MMF to time point after starting MMF. Diff: Difference, SD: standard deviation.